Bayer faces second investor reckoning over glyphosate litigation

FRANKFURT (Reuters) - Bayer on Tuesday faces its second annual investor reckoning over its handling of a wave of U.S. lawsuits claiming its glyphosate-based weedkillers cause cancer.Criticism from investors at this year's annual shareholders' meeting - held in a virtual format as gatherings are banned due to the coronavirus - will likely be less scathing than it was in 2019.Bayer shares have plunged by about a third since August 2018, when the company lost the first U.S. lawsuit claiming..